New insight into the antifibrotic effects of praziquantel on mice in infection with Schistosoma Japonicum

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Liang, Yue Jin ^a   Luo, Jie ^a   Yuan, Quan ^a   Zheng, Dan ^a   Liu, Ya Ping ^a   Shi, Lei ^a   Zhou, Ying ^a   Chen, Ai Ling ^a   Ren, Yong Ya ^a   Sun, Ke Yi ^a   Sun, Yan ^a   Wang, Yong ^a   Zhang, Zhao Song ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA1; COLLAGEN TYPE 3; COLLAGEN TYPE 3 ALPHA1; GAMMA INTERFERON; GELATINASE B; HYDROXYPROLINE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; MESSENGER RNA; PRAZIQUANTEL; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTHELMINTIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COL1ALPHA1 GENE; COL3ALPHA1 GENE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; GAMMA INTERFERON GENE; GENE; GENE EXPRESSION REGULATION; INTERLEUKIN 10 GENE; INTERLEUKIN 13 GENE; INTERLEUKIN 4 GENE; LIVER CELL; LIVER FIBROSIS; LIVER FUNCTION; LOW DRUG DOSE; MATRIX METALLOPROTEINASE 9 GENE; MOUSE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS JAPONICA; SMOOTH MUSCLE ACTIN ALPHA GENE; SPLEEN WEIGHT; SPLENOMEGALY; TISSUE INHIBITOR OF METALLOPROTEINASE 1 GENE; TRANSFORMING GROWTH FACTOR BETA GENE; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; GENETICS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; METABOLISM; PATHOGENICITY; POLYMERASE CHAIN REACTION;

JAPONICA; MURINAE; MUS; SCHISTOSOMA JAPONICUM;

ALANINE TRANSAMINASE; ANIMALS; ANTHELMINTICS; ASPARTATE AMINOTRANSFERASES; CELLS, CULTURED; FEMALE; HYDROXYPROLINE; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MICE; MICE, INBRED BALB C; POLYMERASE CHAIN REACTION; PRAZIQUANTEL; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS JAPONICA;

EID: 79956337629     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020247     Document Type: Article

References (67)

1. Gryseels B, Polman K, Clerinx J, Kestens L, (2006) Human schistosomiasis. Lancet 368: 1106-1118.
2. Cheever AW, (1997) Differential regulation of granuloma size and hepatic fibrosis in schistosome infections. Mem Inst Oswaldo Cruz 92: 689-692.
3. Takemura Y, Kikuchi S, Inaba Y, (1998) Epidemiologic study of the relationship between schistosomiasis due to Schistosoma japonicum and liver cancer/cirrhosis. Am J Trop Med Hyg 59: 551-556.
4. Andrade ZA, (2008) Schistosomiasis and hepatic fibrosis regression. Acta Trop 108: 79-82.
5. Friedman SL, (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669.
6. Friedman SL, (2008) Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88: 125-172.
7. Bartley PB, Ramm GA, Jones MK, Ruddell RG, Li Y, et al. (2006) A contributory role for activated hepatic stellate cells in the dynamics of Schistosoma japonicum egg-induced fibrosis. Int J Parasitol 36: 993-1001.
8. Arthur MJ, Mann DA, Iredale JP, (1998) Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. J Gastroenterol Hepatol 13 (Suppl): S33-38.
9. Breitkopf K, Haas S, Wiercinska E, Singer MV, Dooley S, (2005) Anti-TGF-beta strategies for the treatment of chronic liver disease. Alcohol Clin Exp Res 29: 121S-131S.
10. Cortez-Pinto H, Baptista A, Camilo ME, de Moura MC, (2001) Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis. Hepatogastroenterology 48: 87-90.
11. Tomanovic NR, Boricic IV, Brasanac DC, Stojsic ZM, Delic DS, et al. (2009) Activated liver stellate cells in chronic viral C hepatitis: histopathological and immunohistochemical study. J Gastrointestin Liver Dis 18: 163-167.
12. Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, et al. (2009) Immunopathogenesis of human schistosomiasis. Parasite Immunol 31: 163-176.
13. Fenwick A, Savioli L, Engels D, Robert Bergquist N, Todd MH, (2003) Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 19: 509-515.
14. Stelma FF, Talla I, Sow S, Kongs A, Niang M, et al. (1995) Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg 53: 167-170.
15. WHO (2002) Report of the WHO informal consultation on the use of praziquantel during pregnancy/lactation and albendazole/mebendazole in children under 24 months (WHO/CDS/CPE/PVC/2002.4) Geneva World Health Organization.
16. Morcos SH, Khayyal MT, Mansour MM, Saleh S, Ishak EA, et al. (1985) Reversal of hepatic fibrosis after praziquantel therapy of murine schistosomiasis. Am J Trop Med Hyg 34: 314-321.
17. Berhe N, Myrvang B, Gundersen SG, (2008) Reversibility of schistosomal periportal thickening/fibrosis after praziquantel therapy: a twenty-six month follow-up study in Ethiopia. Am J Trop Med Hyg 78: 228-234.
18. Frenzel K, Grigull L, Odongo-Aginya E, Ndugwa CM, Loroni-Lakwo T, et al. (1999) Evidence for a long-term effect of a single dose of praziquantel on Schistosoma mansoni-induced hepatosplenic lesions in northern Uganda. Am J Trop Med Hyg 60: 927-931.
19. Pinlaor S, Hiraku Y, Yongvanit P, Tada-Oikawa S, Ma N, et al. (2006) iNOS-dependent DNA damage via NF-kappaB expression in hamsters infected with Opisthorchis viverrini and its suppression by the antihelminthic drug praziquantel. Int J Cancer 119: 1067-1072.
20. Xu YL, Huang YX, Yu CX, Liang YS, Wu YY, et al. (2007) Effect of praziquantel on schistosomal ovum granuloma and hepatic fibrosis I Effect of praziquantel on schistosomal ovum granuloma in the lung of mice. Chin J Schisto Control 19: 357-359.
21. Tao FF, Yang YF, Wang H, Sun XJ, Luo J, et al. (2009) Th1-type epitopes-based cocktail PDDV attenuates hepatic fibrosis in C57BL/6 mice with chronic Schistosoma japonicum infection. Vaccine 27: 4110-4117.
22. Zhang L, Yang Y, Yang X, Zhao J, Yang J, et al. (2008) T cell epitope-based peptide-DNA dual vaccine induces protective immunity against Schistosoma japonicum infection in C57BL/6J mice. Microbes Infect 10: 251-259.
23. Yue HY, Yin C, Hou JL, Zeng X, Chen YX, et al. (2010) Hepatocyte nuclear factor 4alpha attenuates hepatic fibrosis in rats. Gut 59: 236-246.
24. Gonzalez-Forero D, Portillo F, Sunico CR, Moreno-Lopez B, (2004) Nerve injury reduces responses of hypoglossal motoneurones to baseline and chemoreceptor-modulated inspiratory drive in the adult rat. J Physiol 557: 991-1011.
25. Weiskirchen R, Gressner AM, (2005) Isolation and culture of hepatic stellate cells. Methods Mol Med 117: 99-113.
26. Bachem MG, Schneider E, Gross H, Weidenbach H, Schmid RM, et al. (1998) Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 115: 421-432.
27. Peterson TC, Rowden G, (1998) Drug-metabolizing enzymes in rat liver myofibroblasts. Biochem Pharmacol 55: 703-708.
28. Shimizu I, Mizobuchi Y, Yasuda M, Shiba M, Ma YR, et al. (1999) Inhibitory effect of oestradiol on activation of rat hepatic stellate cells in vivo and in vitro. Gut 44: 127-136.
29. Mendias CL, Bakhurin KI, Faulkner JA, (2008) Tendons of myostatin-deficient mice are small, brittle, and hypocellular. Proc Natl Acad Sci U S A 105: 388-393.
30. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, et al. (2006) Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 103: 5060-5065.
31. Nagase Y, Iwasawa M, Akiyama T, Kadono Y, Nakamura M, et al. (2009) Anti-apoptotic molecule Bcl-2 regulates the differentiation, activation, and survival of both osteoblasts and osteoclasts. J Biol Chem 284: 36659-36669.
32. Huang XR, Chung AC, Wang XJ, Lai KN, Lan HY, (2008) Mice overexpressing latent TGF-beta1 are protected against renal fibrosis in obstructive kidney disease. Am J Physiol Renal Physiol 295: F118-127.
33. Wu J, Liu J, Waalkes MP, Cheng ML, Li L, et al. (2008) High dietary fat exacerbates arsenic-induced liver fibrosis in mice. Exp Biol Med (Maywood) 233: 377-384.
34. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
35. Constandinou C, Henderson N, Iredale JP, (2005) Modeling liver fibrosis in rodents. Methods Mol Med 117: 237-250.
36. Ross AG, Li YS, Sleigh AC, McManus DP, (1997) Schistosomiasis control in the People's Republic of China. Parasitol Today 13: 152-155.
37. Andersson KL, Chung RT, (2007) Hepatic schistosomiasis Current Treatment Options in Gastroenterology 10: 504-512.
38. Parsons CJ, Takashima M, Rippe RA, (2007) Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol 22 (Suppl 1): S79-84.
39. Homeida MA, el Tom I, Nash T, Bennett JL, (1991) Association of the therapeutic activity of praziquantel with the reversal of Symmers' fibrosis induced by Schistosoma mansoni. Am J Trop Med Hyg 45: 360-365.
40. Reagan-Shaw S, Nihal M, Ahmad N, (2008) Dose translation from animal to human studies revisited. Faseb J 22: 659-661.
41. Abdul-Ghani RA, Hassan AA, (2010) Murine schistosomiasis as a model for human schistosomiasis mansoni: similarities and discrepancies. Parasitol Res 107: 1-8.
42. Maia MD, Lopes EP, Ferraz AA, Barros FM, Domingues AL, et al. (2007) Evaluation of splenomegaly in the hepatosplenic form of mansonic schistosomiasis. Acta Trop 101: 183-186.
43. Rakotonirina E, Andrianjaka P, Rakotoarivelo R, Ramanampamonjy R, Randria M, et al. (2010) Relation between Shistosoma mansoni and hepatosplenomegalies. Sante 20: 15-19.
44. Christian J, Steib MH, Beitinger Frigga, (2010) Amiloride reduces portal hypertension in rat liver cirrhosis. Gut pp. 827-836.
45. Reynaert H, Thompson MG, Thomas T, Geerts A, (2002) Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 50: 571-581.
46. Olds GR, Dasarathy S, (2001) Recent Advances in Schistosomiasis. Curr Infect Dis Rep 3: 59-67.
47. Freitas CR, Barbosa AA Jr, Fernandes AL, Andrade ZA, (1999) Pathology of the spleen in hepatosplenic schistosomiasis. Morphometric evaluation and extracellular matrix changes. Mem Inst Oswaldo Cruz 94: 815-822.
48. Watson M, (2009) Praziquantel Journal of Exotic Pet Medicine 18: 229-231.
49. Biempica L, Dunn MA, Kamel IA, Kamel R, Hait PK, et al. (1983) Liver collagen-type characterization in human schistosomiasis. A histological, ultrastructural, and immunocytochemical correlation. Am J Trop Med Hyg 32: 316-325.
50. Dunn MA, Rojkind M, Warren KS, Hait PK, Rifas L, et al. (1977) Liver collagen synthesis in murine schistosomiasis. J Clin Invest 59: 666-674.
51. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A, (2006) IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 12: 99-106.
52. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, et al. (2007) TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13: 1324-1332.
53. Jacobs W, Kumar-Singh S, Bogers J, Van de Vijver K, Deelder A, et al. (1998) Transforming growth factor-beta, basement membrane components and heparan sulphate proteoglycans in experimental hepatic schistosomiasis mansoni. Cell Tissue Res 292: 101-106.
54. Chu D, Luo Q, Li C, Gao Y, Yu L, et al. (2007) Paeoniflorin inhibits TGF-beta1-mediated collagen production by Schistosoma japonicum soluble egg antigen in vitro. Parasitology 134: 1611-1621.
55. Carpino G, Morini S, Ginanni Corradini S, Franchitto A, Merli M, et al. (2005) Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis 37: 349-356.
56. Coutinho HM, Acosta LP, Wu HW, McGarvey ST, Su L, et al. (2007) Th2 cytokines are associated with persistent hepatic fibrosis in human Schistosoma japonicum infection. J Infect Dis 195: 288-295.
57. Arnaud V, Li J, Wang Y, Fu X, Mengzhi S, et al. (2008) Regulatory role of interleukin-10 and interferon-gamma in severe hepatic central and peripheral fibrosis in humans infected with Schistosoma japonicum. J Infect Dis 198: 418-426.
58. Cheever AW, Williams ME, Wynn TA, Finkelman FD, Seder RA, et al. (1994) Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis. J Immunol 153: 753-759.
59. Kaplan MH, Whitfield JR, Boros DL, Grusby MJ, (1998) Th2 cells are required for the Schistosoma mansoni egg-induced granulomatous response. J Immunol 160: 1850-1856.
60. Kaviratne M, Hesse M, Leusink M, Cheever AW, Davies SJ, et al. (2004) IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol 173: 4020-4029.
61. Gomez DE, De Lorenzo MS, Alonso DF, Andrade ZA, (1999) Expression of metalloproteinases (MMP-1, MMP-2, and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in schistosomal portal fibrosis. Am J Trop Med Hyg 61: 9-13.
62. Hemmann S, Graf J, Roderfeld M, Roeb E, (2007) Expression of MMPs and TIMPs in liver fibrosis- a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 46: 955-975.
63. Roderfeld M, Weiskirchen R, Wagner S, Berres ML, Henkel C, et al. (2006) Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. Faseb J 20: 444-454.
64. Knittel T, Mehde M, Kobold D, Saile B, Dinter C, et al. (1999) Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J Hepatol 30: 48-60.
65. Giannelli G, Bergamini C, Marinosci F, Fransvea E, Napoli N, et al. (2006) Antifibrogenic effect of IFN-alpha2b on hepatic stellate cell activation by human hepatocytes. J Interferon Cytokine Res 26: 301-308.
66. Han YP, Zhou L, Wang J, Xiong S, Garner WL, et al. (2004) Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem 279: 4820-4828.
67. Moreno M, Gonzalo T, Kok RJ, Sancho-Bru P, van Beuge M, et al. (2010) Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 51: 942-952.